DK0810880T3 - Præparater og assays, hvor der anvendes subunits af enzymer - Google Patents
Præparater og assays, hvor der anvendes subunits af enzymerInfo
- Publication number
- DK0810880T3 DK0810880T3 DK96903111T DK96903111T DK0810880T3 DK 0810880 T3 DK0810880 T3 DK 0810880T3 DK 96903111 T DK96903111 T DK 96903111T DK 96903111 T DK96903111 T DK 96903111T DK 0810880 T3 DK0810880 T3 DK 0810880T3
- Authority
- DK
- Denmark
- Prior art keywords
- agent
- constituted
- components
- subunits
- assays
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 238000003556 assay Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 235000019626 lipase activity Nutrition 0.000 abstract 2
- 125000003473 lipid group Chemical group 0.000 abstract 2
- 108010081427 Clostridium perfringens alpha toxin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pathology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9503486.4A GB9503486D0 (en) | 1995-02-22 | 1995-02-22 | Pharmaceuticals and assays using enzyme subunits |
| PCT/GB1996/000380 WO1996025952A1 (en) | 1995-02-22 | 1996-02-21 | Pharmaceuticals and assays using enzyme subunits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0810880T3 true DK0810880T3 (da) | 2003-01-06 |
Family
ID=10770034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96903111T DK0810880T3 (da) | 1995-02-22 | 1996-02-21 | Præparater og assays, hvor der anvendes subunits af enzymer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6472365B1 (da) |
| EP (1) | EP0810880B1 (da) |
| JP (1) | JPH11500136A (da) |
| KR (1) | KR19980702499A (da) |
| CN (1) | CN1188704C (da) |
| AT (1) | ATE224204T1 (da) |
| AU (1) | AU714396B2 (da) |
| CA (1) | CA2213566A1 (da) |
| DE (1) | DE69623755T2 (da) |
| DK (1) | DK0810880T3 (da) |
| ES (1) | ES2182962T3 (da) |
| GB (1) | GB9503486D0 (da) |
| PT (1) | PT810880E (da) |
| WO (1) | WO1996025952A1 (da) |
| ZA (1) | ZA961427B (da) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4463090A (en) * | 1981-09-30 | 1984-07-31 | Harris Curtis C | Cascade amplification enzyme immunoassay |
| US4900556A (en) | 1985-04-26 | 1990-02-13 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| GB8528761D0 (en) * | 1985-11-22 | 1985-12-24 | Axon Healthcare Ltd | Enzyme-coupled antibodies |
| US4874710A (en) * | 1986-02-20 | 1989-10-17 | Becton Dickinson And Company | Assay and product in which binder and liposomes are supported on a solid support |
| EP0301333A3 (en) | 1987-07-29 | 1992-07-01 | Abbott Laboratories | Liposome based homogeneous immunoassay for diagnostic tests |
| US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| JPH04200632A (ja) | 1990-11-29 | 1992-07-21 | Toyo Ink Mfg Co Ltd | リポソームの破壊方法 |
| JPH0556797A (ja) | 1991-08-31 | 1993-03-09 | Toyo Ink Mfg Co Ltd | リポソーム破壊物質の検出方法 |
| US5277913A (en) * | 1991-09-09 | 1994-01-11 | Thompson David H | Liposomal delivery system with photoactivatable triggered release |
| DE69407292T2 (de) * | 1993-06-30 | 1998-06-25 | Genentech Inc | Verfahren zur herstellung von liposomen |
-
1995
- 1995-02-22 GB GBGB9503486.4A patent/GB9503486D0/en active Pending
-
1996
- 1996-02-21 US US08/894,527 patent/US6472365B1/en not_active Expired - Fee Related
- 1996-02-21 CA CA002213566A patent/CA2213566A1/en not_active Abandoned
- 1996-02-21 AT AT96903111T patent/ATE224204T1/de not_active IP Right Cessation
- 1996-02-21 EP EP96903111A patent/EP0810880B1/en not_active Expired - Lifetime
- 1996-02-21 DE DE69623755T patent/DE69623755T2/de not_active Expired - Fee Related
- 1996-02-21 WO PCT/GB1996/000380 patent/WO1996025952A1/en not_active Ceased
- 1996-02-21 KR KR1019970705899A patent/KR19980702499A/ko not_active Abandoned
- 1996-02-21 ES ES96903111T patent/ES2182962T3/es not_active Expired - Lifetime
- 1996-02-21 CN CNB961934344A patent/CN1188704C/zh not_active Expired - Fee Related
- 1996-02-21 JP JP8525485A patent/JPH11500136A/ja not_active Withdrawn
- 1996-02-21 PT PT96903111T patent/PT810880E/pt unknown
- 1996-02-21 DK DK96903111T patent/DK0810880T3/da active
- 1996-02-21 AU AU47259/96A patent/AU714396B2/en not_active Ceased
- 1996-02-22 ZA ZA961427A patent/ZA961427B/xx unknown
-
2001
- 2001-11-21 US US09/989,130 patent/US6974699B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69623755D1 (de) | 2002-10-24 |
| US20020035084A1 (en) | 2002-03-21 |
| WO1996025952A1 (en) | 1996-08-29 |
| ES2182962T3 (es) | 2003-03-16 |
| CA2213566A1 (en) | 1996-08-29 |
| JPH11500136A (ja) | 1999-01-06 |
| AU4725996A (en) | 1996-09-11 |
| EP0810880B1 (en) | 2002-09-18 |
| EP0810880A1 (en) | 1997-12-10 |
| ZA961427B (en) | 1996-08-07 |
| PT810880E (pt) | 2003-02-28 |
| US6472365B1 (en) | 2002-10-29 |
| ATE224204T1 (de) | 2002-10-15 |
| GB9503486D0 (en) | 1995-04-12 |
| AU714396B2 (en) | 2000-01-06 |
| DE69623755T2 (de) | 2003-06-05 |
| US6974699B2 (en) | 2005-12-13 |
| KR19980702499A (ko) | 1998-07-15 |
| CN1188704C (zh) | 2005-02-09 |
| CN1182372A (zh) | 1998-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bade et al. | Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates | |
| BR9713521A (da) | ||
| ES2171705T3 (es) | Complejos de polipeptido-dendrimero. | |
| DE69407402D1 (de) | Repamycinbestimmung | |
| Mary et al. | Posttranslational Modifications in the C-terminal Tail of Axonemal Tubulin from Sea Urchin Sperm (∗) | |
| DK261386A (da) | Monoklonale antistoffer | |
| WEIR et al. | Destruction of endogenous peroxidase activity in order to locate cellular antigens by peroxidase-labeled antibodies | |
| DE60044420D1 (de) | Enzym-Protein-Komplex | |
| BR9709958A (pt) | Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso | |
| Rascón et al. | Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle | |
| ES2136598T3 (es) | Inmunoanalisis de deteccion de anticuerpos monoclonales contra los peptidos de activacion de protrombina y sus productos de degradacion. | |
| DK0810880T3 (da) | Præparater og assays, hvor der anvendes subunits af enzymer | |
| Enjyoji et al. | Purification and characterization of rat T-kininogens isolated from plasma of adjuvant-treated rats. Identification of three kinds of T-kininogens. | |
| Shime et al. | Association of Pasteurella multocida toxin with vimentin | |
| Choumet et al. | Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of Bungarus fasciatus by genetic recombination | |
| Primiano et al. | Enhanced expression, purification, and characterization of a novel class α glutathione S-transferase isozyme appearing in rabbit hepatic cytosol following treatment with 4-picoline | |
| ES2060146T3 (es) | Metaloproteinasas colagenoliticas asociadas con metastasis. | |
| CO5300499A1 (es) | Ensayo de inmunoabsorbente ligado a enzima de inhibicion (elisa) para deteccion y cuantificacion de anticuerpos en muestras biologicas | |
| Barrieux et al. | Nonidentity of the 48,000-dalton protein of mRNA-protein particles and the beta subunit of eukaryotic initiation factor 2. | |
| Perpetuo et al. | Development of an operational synaptobrevin‐based fluorescent substrate for tetanus neurotoxin quantification | |
| Smales et al. | Purification and characterization of lysozyme‐pregnanediol glucuronide conjugates: the effect of the hapten and coupling reagent on the substitution level, sites of acylation and the consequences for the development of future immunoassays | |
| DE60029570D1 (de) | Verfahren zur isolierung der cd8+-zellen, und entsprechende hybridomazellen, antikörper und polypeptide | |
| Klugerman | CHEMICAL AND PHYSICAL VARIABLES AFFECTING FLUORESCEIN ISOTHIOCYANATE AND ITS PROTEIN CONJUGATES | |
| BRPI9715268B8 (pt) | preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção | |
| Kakizaki et al. | A sandwich enzyme immunoassay for human pancreatic elastase III |